A5048513152- Bladder and Urothelial Cancer Treatments
- Prostate Cancer Diagnosis and Treatment
- Prostate Cancer Treatment and Research
- Urinary and Genital Oncology Studies
- Advanced Radiotherapy Techniques
- Urological Disorders and Treatments
- Radiation Therapy and Dosimetry
- Renal cell carcinoma treatment
- Global Cancer Incidence and Screening
- Esophageal Cancer Research and Treatment
- Cancer Immunotherapy and Biomarkers
- Advances in Oncology and Radiotherapy
- Multiple and Secondary Primary Cancers
- Tissue Engineering and Regenerative Medicine
- Testicular diseases and treatments
- Economic and Financial Impacts of Cancer
- Cancer, Lipids, and Metabolism
- Radiomics and Machine Learning in Medical Imaging
- Urologic and reproductive health conditions
- Health Systems, Economic Evaluations, Quality of Life
- Lung Cancer Treatments and Mutations
- Estrogen and related hormone effects
- Cancer Genomics and Diagnostics
- Cervical Cancer and HPV Research
- Cancer Diagnosis and Treatment
Massachusetts General Hospital
2016-2025
Harvard University
2016-2025
Brigham and Women's Hospital
2005-2025
Mass General Brigham
2025
Dana-Farber/Harvard Cancer Center
2021-2023
University Hospitals Seidman Cancer Center
2016-2022
University College London
2022
Ospedale Regionale di Bellinzona e Valli
2022
Cancer Trials Ireland
2022
University of Ulster
2022
PURPOSE To test the hypothesis that increasing radiation dose delivered to men with early-stage prostate cancer improves clinical outcomes. PATIENTS AND METHODS Men T1b-T2b and prostate-specific antigen </= 15 ng/mL were randomly assigned a total of either 70.2 Gray equivalents (GyE; conventional) or 79.2 GyE (high). No patient received androgen suppression therapy radiation. Local failure (LF), biochemical (BF), overall survival (OS) Results A 393 assigned, median follow-up was 8.9 years....
This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Bladder Cancer focuses on clinical presentation and workup of suspected bladder cancer, treatment non–muscle-invasive urothelial metastatic cancer because important updates have recently been made to these sections. Some include recommendations optimal event a bacillus Calmette-Guérin (BCG) shortage details about biomarker testing advanced or disease. The systemic therapy second-line subsequent...
Multiple prospective Radiation Therapy Oncology Group (RTOG) protocols have evaluated bladder-preserving combined-modality therapy (CMT) for muscle-invasive bladder cancer (MIBC), reserving cystectomy salvage treatment. We performed a pooled analysis of long-term outcomes in patients with MIBC enrolled across multiple studies.Four hundred sixty-eight were onto six RTOG bladder-preservation studies, including five phase II studies (RTOG 8802, 9506, 9706, 9906, and 0233) one III study 8903)....
We aimed to update a previously published, multi-institutional nomogram of outcomes for salvage radiotherapy (SRT) following radical prostatectomy (RP) prostate cancer, including patients treated in the contemporary era.Individual data from node-negative with detectable post-RP prostate-specific antigen (PSA) SRT or without concurrent androgen-deprivation therapy (ADT) were obtained 10 academic institutions. Freedom biochemical failure (FFBF) and distant metastases (DM) rates estimated,...
This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Bladder Cancer focuses on systemic therapy muscle-invasive urothelial bladder cancer, as substantial revisions were made 2017 updates, such new recommendations nivolumab, pembrolizumab, atezolizumab, durvalumab, and avelumab. The complete version of addresses additional aspects management including non-muscle-invasive cancer nonurothelial histologies, well staging, evaluation, follow-up.
The NCCN Clinical Practice Guidelines in Oncology for Bladder Cancer provide recommendations the diagnosis, evaluation, treatment, and follow-up of patients with bladder cancer. These Insights discuss important updates to 2018 version guidelines, including implications 8th edition AJCC Staging Manual on treatment muscle-invasive cancer incorporating newly approved immune checkpoint inhibitor therapies into options locally advanced or metastatic disease.
inclusive of all proper methods care or exclusive other reasonably directed to obtaining the same results.The physician must make ultimate judgment regarding any specific therapy
Decipher (Decipher Biosciences Inc) is a genomic classifier (GC) developed to estimate the risk of distant metastasis (DM) after radical prostatectomy (RP) in patients with prostate cancer.To validate GC context randomized phase 3 trial.This ancillary study used RP specimens from placebo-controlled NRG/RTOG 9601 clinical trial conducted March 1998 2003. The were centrally reviewed, and RNA was extracted highest-grade tumor available 2019 median follow-up 13 years. Clinical-grade whole...